Overview

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B). Cohort B is complete and no longer recruiting subjects.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Progenics Pharmaceuticals, Inc.